This company listing is no longer active
Amniotics Management
Management criteria checks 2/4
Amniotics' CEO is Marcus Larsson, appointed in Aug 2022, has a tenure of 2.08 years. directly owns 20.38% of the company’s shares, worth SEK3.01M. The average tenure of the management team and the board of directors is 2.1 years and 3.7 years respectively.
Key information
Marcus Larsson
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.1yrs |
| CEO ownership | 20.4% |
| Management average tenure | 2.1yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
CEO
Marcus Larsson (51 yo)
2.1yrs
Tenure
Mr. Marcus Larsson, Ph D., has been a Director of Amniotics AB (publ) since 2015 and serves as its Chief Executive Officer from August 2022. He is also Chairman of the Board of Camurus Lipid Research Found...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founding Member | 2.1yrs | no data | 20.38% SEK 3.0m | |
| Chief Financial Officer | 1.3yrs | no data | no data | |
| Chief Operating Officer | 7.7yrs | no data | 0.27% SEK 39.3k | |
| Head of Manufacturing | no data | no data | no data |
2.1yrs
Average Tenure
52yo
Average Age
Experienced Management: AMNI's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founding Member | 9.7yrs | no data | 20.38% SEK 3.0m | |
| Independent Chairman of the Board | 3.7yrs | no data | 0.91% SEK 135.0k | |
| Independent Director | 3.7yrs | no data | 0.055% SEK 8.1k | |
| Independent Director | 3.7yrs | no data | 2.6% SEK 383.6k | |
| Independent Director | 3.7yrs | no data | no data |
3.7yrs
Average Tenure
61yo
Average Age
Experienced Board: AMNI's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/30 13:36 |
| End of Day Share Price | 2024/09/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amniotics AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carl Ramanius | Redeye |